경희대학교 의과대학졸
경희대학교 부속병원 수련의
경희대학교 부속병원 비뇨기과전공의
경북안동종합병원 비뇨기과 과장
중앙대학교 부속 용산병원 남성과학연구원
박병대비뇨기과의원 원장
서초구의사회 정보이사역임
현 대한비뇨기과학회 정보위원
현 대한비뇨기과개원의협의회 상임이사(정보이사)
대한남성과학회 대한비뇨기종양학회 대한소아비뇨기과학회
대한배뇨장애학회 및 요실금학회 대한Endourology학회
대한전립선학회 대한비뇨기과개원의협의회
대한요로생식기감염학회

상기학회 정회원

남성과학 논문
Paper

Risk Factors for an Early Increase in Dose of Vasoactive Agents for Intracavernous Pharmacotherapy
Sae Chul Kim, Kyung Keun Seo, Byung Dae Park, Sung Woon Lee
Department of Urology, College of Medicine, Chung-Ang University, Seoul, Korea

Urologia Internationalis 65:4:2000, 204-207.

Abstract
Aims: This study was to identify factors that influence the early increase in the dose of intracavernous vasoactive agents to maintain erection for satisfactory intercourse and to elucidate when the dose increase would begin. Methods: Seventy-nine patients using intracavernous pharmacotherapy with tri-mix (PGE1, papaverine, and phentolamine) over a 3- to 4-year period were enrolled. At 3-month intervals, patients were questioned about changes in dose to maintain erection for satisfactory intercourse and frequency of injection, and underwent examination of the penis. The patients were divided into 2 groups: group A, dose increase of 20% after initiating home therapy, and group B, no change or an increase in dose <20%. Results: A significant increase (p < 0.01) in dose was started 2-3 years after initiating pharmacotherapy. The initial doses of group A at 2-3 and 3-4 years were significantly higher than those of group B (p < 0.01). There were no significant differences in the age of the patients, duration of erectile dysfunction, incidence of accompanying vascular risk factors, frequency of injection, or incidence of fibrous plaques between group A and group B, both at 2-3 and 3-4 years. Conclusion: The initial dose of intracavernous vasoactive agents (tri-mix) may be a unique risk factor for the early increase in dose to maintain erection for satisfactory intercourse.

Copyright © 2000 S. Karger AG, Basel